These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22988037)

  • 1. Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center.
    Lee DH; Jung HB; Lee SH; Rha KH; Choi YD; Hong SJ; Yang SC; Chung BH
    Jpn J Clin Oncol; 2012 Nov; 42(11):1079-85. PubMed ID: 22988037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
    Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
    BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols.
    Kim TH; Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    Int J Urol; 2014 Apr; 21(4):377-81. PubMed ID: 24168232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient selection and pathological outcomes using currently available active surveillance criteria.
    El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
    BJU Int; 2013 Aug; 112(4):471-7. PubMed ID: 23746382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort.
    Smaldone MC; Cowan JE; Carroll PR; Davies BJ
    J Urol; 2010 Jan; 183(1):138-43. PubMed ID: 19913808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance criteria for prostate cancer: can they be applied to Japanese patients?
    Goto Y; Nozumi K; Miyazaki K; Matsumoto A; Inoue A; Kito H; Hasegawa N; Nagata M; Kakuta Y; Suzuki H; Yamaguchi K
    Int J Urol; 2012 Feb; 19(2):163-6. PubMed ID: 22070372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols.
    Komisarenko M; Timilshina N; Richard PO; Alibhai SM; Hamilton R; Kulkarni G; Zlotta A; Fleshner N; Finelli A
    J Urol; 2016 Dec; 196(6):1645-1650. PubMed ID: 27350077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort.
    Sugimoto M; Shiraishi T; Tsunemori H; Demura T; Saito Y; Kamoto T; Kakehi Y
    Jpn J Clin Oncol; 2010 Oct; 40(10):973-9. PubMed ID: 20534686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
    Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
    J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological outcomes of candidates for active surveillance of prostate cancer.
    Conti SL; Dall'era M; Fradet V; Cowan JE; Simko J; Carroll PR
    J Urol; 2009 Apr; 181(4):1628-33; discussion 1633-4. PubMed ID: 19233388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: comparison of six different active surveillance protocols.
    Tsang CF; Tsu JH; Lai TC; Wong KW; Ho BS; Ng AT; Ma WK; Yiu MK
    Hong Kong Med J; 2017 Dec; 23(6):609-15. PubMed ID: 29026057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological findings at radical prostatectomy in patients initially managed by active surveillance: a comparative analysis.
    Iremashvili V; Manoharan M; Rosenberg DL; Acosta K; Soloway MS
    Prostate; 2012 Oct; 72(14):1573-9. PubMed ID: 22415945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score.
    Fine SW; Epstein JI
    J Urol; 2008 Apr; 179(4):1335-8; discussion 1338-9. PubMed ID: 18289601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance.
    O'Brien BA; Cohen RJ; Ryan A; Sengupta S; Mills J
    J Urol; 2011 Nov; 186(5):1811-7. PubMed ID: 21944097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatectomy pathology findings in an active surveillance population.
    Ramirez-Backhaus M; Iborra I; Gomez-Ferrer A; Rubio-Briones J
    Arch Esp Urol; 2014 Jun; 67(5):431-9. PubMed ID: 24914842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
    Reese AC; Landis P; Han M; Epstein JI; Carter HB
    J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.